Yoga to Improve Disparities in Cancer Survivorship

NCT07165600 | Active Not Recruiting

• 2 other identifiers: 25802NCI-2025-05225
• Study Type: interventional
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial tests the impact of a racially concordant trainer led yoga program on quality of life and symptom burden in Black and/or African American cancer survivors. Black individuals in the United States are more affected by cancer, despite modern advances. Cancer treatments can impact physical and mental health and overall quality of life and Black individuals report worse physical function and quality of life and less access to culturally appropriate support services. Yoga has been shown to have a positive impact on cancer and cancer treatment related symptoms and quality of life, however, a one size fits all approach has not been shown to be effective in diverse populations. A trainer that shares the same racial or ethnic background as the participant (racially concordant) may have a positive impact on communication, trust, and may improve accessibility and participation. Participating in a yoga program led by a racially concordant trainer may improve quality of life and symptom burden in Black and/or African American cancer survivors.

Conditions

Survivorship; Cancer

Keywords

Cultural support services

Outcome Measures

Primary Outcomes (4)

• Overall completion rate

  The completion rate is defined as the proportion of enrolled individuals who attend at least 2 yoga sessions.

  Up to 8 weeks

• Median score on the Feasibility of Intervention Measure (FIM)

  The FIM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is \>= 4.

  Up to 8 weeks

• Median score on the Acceptability of Intervention Measure (AIM)

  The AIM is a four-item measure of implementation that assesses participants perceived acceptability of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is \>= 4.

  Up to 8 weeks

• Median score on the Intervention Appropriateness Measure (IAM)

  The IAM is a four-item measure of implementation that assesses participants perceived appropriateness of the intervention. Each item response falls on a scale of 1 (Completely disagree) to 5 (Completely agree). A scaled score is calculated by averaging responses. Scale values range from 1 to 5. The intervention will be determined acceptable if the overall median score is \>= 4.

  Up to 8 weeks

Secondary Outcomes (2)

• Change in scores on the Patient Reported Outcomes Measurement Information System (PROMIS®-29) (Version 2) score

  Up to 8 weeks

• Percentage of participants reporting adverse events

  Up to 8 weeks

Study Arms (1)

Yoga Intervention

EXPERIMENTAL

Participants receive a 4-week yoga intervention consisting of weekly 60-minute yoga sessions led by a trained facilitator. Participants may also participate remotely. At the end of the program, participants will also receive access to online yoga training videos (created by the study team) to continue self-practice.

Other: Yoga

Interventions

Yoga OTHER

Physical activity

Also known as: Yoga training, Yoga sessions

Yoga Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \>=18 years.
• Able to understand study procedures and to comply with them for the entire length of the study.
• Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.
• Diagnosed with any malignancy and/or received any cancer directed therapy within 5 years of enrollment.
• Be able to speak, read and write in English.
• Self-identify as Black or African American race.
• Reside in California.

You may not qualify if:

• Contraindication to any study-related procedure or assessment.
• a. Participants complete the PAR-Q at screening to ensure that they are physically well enough to enroll in the study. If they report any conditions that may be contraindications to physical activity, physician clearance will be required prior to enrollment.
• Planned major surgery during the study period.
• Any major injuries that limit physical activity.
• Active or radiographic evidence of cancer requiring treatment during the study period. Adjuvant therapy is allowed (including hormonal, immuno-, or targeted therapy). Ongoing treatment such as hormone or maintenance therapies including HER2 directed, or immunotherapy are only allowed if patient has no evidence of disease on most recent imaging.

Sponsors & Collaborators

• University of California, San Francisco: lead

Study Sites (1)

University of California, San Francisco

San Francisco, California, 94143, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Yoga

Intervention Hierarchy (Ancestors)

Mind-Body Therapies; Complementary Therapies; Therapeutics; Spiritual Therapies; Exercise Movement Techniques; Physical Therapy Modalities

Study Officials

• Sorbarikor Piawah, MD, MPH

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

• Chloe Atreya, MD, PhD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 3, 2025
• First Posted: September 10, 2025
• Study Start: September 24, 2025
• Primary Completion: May 15, 2026
• Study Completion: May 15, 2026
• Last Updated: May 15, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)